1. Home
  2. PCG vs ILMN Comparison

PCG vs ILMN Comparison

Compare PCG & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pacific Gas & Electric Co.

PCG

Pacific Gas & Electric Co.

HOLD

Current Price

$14.15

Market Cap

36.0B

Sector

Utilities

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$218.57

Market Cap

32.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCG
ILMN
Founded
1995
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Power Generation
Medical Specialities
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.0B
32.3B
IPO Year
2000
2000

Fundamental Metrics

Financial Performance
Metric
PCG
ILMN
Price
$14.15
$218.57
Analyst Decision
Buy
Hold
Analyst Count
8
17
Target Price
$22.19
$124.24
AVG Volume (30 Days)
42.8M
1.7M
Earning Date
04-23-2026
04-30-2026
Dividend Yield
1.22%
N/A
EPS Growth
2.61
170.87
EPS
0.72
2.22
Revenue
$24,935,000,000.00
$4,343,000,000.00
Revenue This Year
$7.24
$6.47
Revenue Next Year
$3.41
$5.58
P/E Ratio
$19.45
$98.09
Revenue Growth
2.11
N/A
52 Week Low
$12.59
$88.00
52 Week High
$19.16
$231.81

Technical Indicators

Market Signals
Indicator
PCG
ILMN
Relative Strength Index (RSI) 33.05 59.45
Support Level N/A $117.73
Resistance Level $16.82 $231.81
Average True Range (ATR) 0.80 9.22
MACD -0.50 -0.37
Stochastic Oscillator 24.33 68.24

Price Performance

Historical Comparison
PCG
ILMN

About PCG Pacific Gas & Electric Co.

PG&E is a holding company whose main subsidiary is Pacific Gas and Electric, a regulated utility operating in Central and Northern California that serves 5.3 million electricity customers and 4.6 million gas customers in 47 of the state's 58 counties. PG&E operated under bankruptcy court supervision in 2001-04 during California's energy crisis and in 2019-20 due to wildfire losses. In 2004, PG&E sold its unregulated assets as part of its first postbankruptcy reorganization.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: